Sorafenib-induced hepatic encephalopathy.
Marks
Anne-Bérengère
AB
Gerard
Romain
R
Fournier
Peggy
P
Coupe
Patrick
P
Gautier
Sophie
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006501:Hepatic Encephalopathy / Q000139:chemically induced*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib; D013997:Time Factors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib